ViewRNATM eZ Assays, fully automated on the
Leica BOND RX, offer remarkable sensitivity and specificity of staining
for coding and non-coding markers in an easy-to-use, fully automated
The Leica BOND RX system automates the staining process, bringing all the benefits of consistency, reduced labor, and speed. This fully automated assay is hands-free from tissue de-waxing to counter staining, and offers high sensitivity, specificity, and reproducibility with easy standardization across laboratories. ViewRNA eZ Assays represent a major technological advancement offering a robust and reliable platform to easily interrogate the function and disease relevance of any expressed genes.
“In particular, the ability to target non-coding as well as coding transcripts opens up a significant new capability to discover powerful new biomarkers for molecular test development, as the importance of the non-coding regions of the transcriptome are becoming more and more evident,” said
Affymetrix’ ViewRNA eZ Assays on the Leica BOND RX platform are now available for research applications. The ViewRNA eZ staining protocol is pre-loaded onto the Leica BOND RX, and the staining kit optimized for FFPE samples and probes of choice are available from
*For Research Use Only. Not for use in diagnostic procedures.
About Leica Biosystems
Leica Biosystems is a global leader in workflow solutions and automation, striving to advance cancer diagnostics to improve patients’ lives. Leica Biosystems provides anatomical pathology laboratories and researchers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. Leica’s easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence. The company is represented in over 100 countries and is headquartered in Nussloch,
The Company provides leadership and support, partnering with customers in pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and non-profit research institutes in their quest to use biology for a better world.
More than 2,300 microarray systems have been shipped around the world and more than 65,000 peer-reviewed papers have been published citing
All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding
Vice President, Marketing Services
Vice President, Investor Relations
Most Popular Stories
- National Retail Federation Reduces Sales Forecast
- Hispanic Leader Goes the Extra Mile
- Xavier Gutierrez Appointed to Bank Board
- Long-term Strengths Emerge in U.S. Economy
- Honda' s Accord Plug-in Hybrid Is a Fuel Miser
- Morgan Stanley Ponies Up $275 Million to Settle SEC Charges
- Stop-Start Engines Save Gas, Reduce Emissions
- Weekly Jobless Claims Drop to Lowest Level in 8 Years
- Ted Cruz: Why Did FAA Ban Flights to Israel?
- Naya Rivera and Ryan Dorsey Are Married